

Stylianos BOURNAZOS, Ph.D.

The Rockefeller University,
1230 York Avenue, Box 98
New York, NY 10065
t: +1-212-327-7310
c: +1-917-385-6480

e: sbournazos@rockefeller.edu

www.linkedin.com/in/stylianos-bournazos

Education

BSc (Hons) in Genetics – Immunology (First Class Honors) University of Aberdeen, Aberdeen, United Kingdom	2002 – 2005
MSc (by Research) in Life Sciences (with Distinction) University of Edinburgh, Edinburgh, United Kingdom	2005 – 2006
PhD in Immunology University of Edinburgh, Edinburgh, United Kingdom	2006 – 2010
Postdoctoral Training The Rockefeller University, New York, NY	2010 – 2015

Positions and Appointments

2021 – present	Research Associate Professor , The Rockefeller University, Laboratory of Molecular Genetics and Immunology, New York, NY
2021 – present	Consultant , Truffle Capital / SpikImm, Paris, France
2016 – 2021	Research Assistant Professor , The Rockefeller University, Laboratory of Molecular Genetics and Immunology, New York, NY
2015 – 2016	Research Associate , The Rockefeller University, Laboratory of Molecular Genetics and Immunology, New York, NY
2013 – 2015	Postdoctoral Fellow , The Rockefeller University, Laboratory of Molecular Genetics and Immunology, New York, NY
2010 – 2013	Postdoctoral Associate , The Rockefeller University, Laboratory of Molecular Genetics and Immunology, New York, NY
2006 – 2010	Graduate Research Fellow , MRC Center for Inflammation Research, Edinburgh, United Kingdom
2006 – 2009	Clinical Research Assistant , Department of Cardiology, NHS Lothian Royal Infirmary of Edinburgh, United Kingdom
2005 – 2006	MSc Research Student , University of Edinburgh/British Heart Foundation Center for Cardiovascular Science, Edinburgh, United Kingdom
2004 – 2005	Undergraduate Research Fellow , University of Aberdeen, United Kingdom

Honors and Awards

University of Aberdeen Brenda Page Memorial Prize in Genetics 2005
 British Heart Foundation MSc/PhD Fellowship 2005-2009
 University of Edinburgh Center for Cardiovascular Science Travel Fellowship 2005
 Biochemical Society Student Travel Grant 2008
 IUBMB-FEBS Travel Bursary 2008
 British Heart Foundation Travel Fellowship 2008, 2009
 NIH-Northeast Biodefense Center (NBC) Career Development Award 2011
 American Heart Association Founders Affiliate Postdoctoral Research Fellowship 2013
 amfAR Mathilde Krim Fellowship in Basic Biomedical Research 2014
 Gilead Sciences HIV Scholar Award 2017

Patents

Issued and pending applications

US 62/262,091 WO2017096221A1 "Bispecific anti-HIV broadly neutralizing antibodies"
 Stylianos Bournazos, Michel C. Nussenzweig, Jeffrey V. Ravetch
 US 16/424,639 US20190300621A1 "Human IgG Fc domain variants with improved effector function"
 Jeffrey V. Ravetch, Stylianos Bournazos
 US 17/617,901 "Antibodies and methods for treatment of viral infections"
 Jeffrey V. Ravetch, Stylianos Bournazos
 US 63/160,054 "Diagnosis and treatment of dengue virus infection"
 Stylianos Bournazos, Jeffrey V. Ravetch
 US 22/19,743 "Glycoform specific nanobodies and methods of use"
 Stylianos Bournazos, Jeffrey V. Ravetch

Academic Activities

Mentoring

Current service:

Serving as supervisor for Ms Estelle Yao, PhD student from the Tri-Institutional (RU/MSKCC/Cornell) PhD Program

Member of the thesis committee of Ms Cindy Rodriguez, PhD candidate from the MSK-Hunter College graduate program

Past service:

Served as the graduate student mentor and supervisor for the following graduate rotation students and undergraduate trainees:

- Max Chomet, 1st year rotation student from the Cornell University graduate school (Department of Immunology), 05/2013 – 09/2013
- Harlan Pietz, MD-PhD Student, Weill Cornell/Rockefeller/Sloan Kettering, Tri-Institutional MD-PhD Program, 05/2017 – 08/2017
- Noah Perlmutter, visiting BS student from Washington University in St. Louis, 06/2018 – 07/2018
- Kevin Kao, MD-PhD Student, Weill Cornell/Rockefeller/Sloan Kettering, Tri-Institutional MD-PhD Program, 07/2018 – 12/2022

- Aaron Gupta, MD-PhD Student, Weill Cornell/Rockefeller/Sloan Kettering, Tri-Institutional MD-PhD Program, 07/2018 – 12/2022
- William Doyle, PhD Student, Rockefeller University graduate program, 01/2023 – 03/2023

Editorial

Reviewer for PLoS One, Journal of Experimental Medicine, Lung, Cell reports, Cell Host & Microbe, International Archives of Allergy and Immunology, European Journal of Immunology, The Journal of Immunology, Nature microbiology, Nature Communications, Frontiers in Immunology, Immunity, Cell Reports Medicine, iScience, EBioMedicine, Scientific Reports

Grant Reviewer

National Cancer Institute:

Member of the Special Emphasis Panel/Scientific Review Group 2020/08 ZCA1 GRB-I (A)

National Institute on Aging:

Member of the Special Emphasis Panel/Scientific Review Group 2021/01 ZAG1 ZIJ-U (J1)

Medical Research Council (MRC), United Kingdom

Deutsche Forschungsgemeinschaft (DFG), Germany

Israeli Ministry of Innovation, Science and Technology, Israel

Invited speaker at scientific meetings

AIDS vaccine 2012 conference, Boston, MA

8th CAVD (The Collaboration for AIDS Vaccine Discovery) meeting 2013, Seattle, WA

Keystone HIV Vaccines 2016, Olympic Valley, CA

6th International Conference on Osteoimmunology: Interactions of the Immune and Skeletal Systems, Chania, Greece

HIVR4P 2016 / Canadian Alliance Coordinating Office, Chicago, IL

11th CAVD (The Collaboration for AIDS Vaccine Discovery) meeting 2016, Seattle, WA

Keystone Biobetters and Next-Generation Biologics: Innovative Strategies for Optimally Effective Therapies 2017, Snowbird, UT

NIAID Workshop on Mechanisms of Fc-Dependent, Antibody-Mediated Killing, Rockville, MD

2nd Next-Generation Antibodies and Protein Analysis 2017, Gent, Belgium

PEGS Europe: Protein & Antibody Engineering Summit, 2017, Lisbon, Portugal

Gilead Research Scholars Day, 2018, San Francisco, CA

EMBO Workshop on Antibodies and complement: Effector functions, therapies and technologies, Girona, Spain

PEGS: the essential protein engineering summit, 2019, Boston MA

NIAID Workshop on Genetically Engineered Mouse Models to Accelerate HIV Vaccine Development, 2021

WHO Expert Group for the development of preclinical models of COVID-19 disease, 2021

NIAID Workshop on Clinical Development of Broadly Neutralizing Antibodies (bnAb) for HIV-1, 2022

Memberships

Member, British Society for Immunology 2005

Member, Biochemical Society (UK) 2005

Member of the Scottish Cardiovascular Forum 2005

Organizing committee member, Biochemical Society – Dynamic Cell Conference, Edinburgh, UK 2009

New York Academy of Science – Science Alliance for Postdocs and Graduate Students 2010

Member, American Heart Association 2012

Member, American Association of Immunologists 2016

Member, New York Academy of Science 2016

Organizing committee member, NIAID Workshop on Genetically Engineered Mouse Models to Accelerate HIV Vaccine Development, 2021

Member, WHO Expert Group for the development of preclinical models of COVID-19 disease, 2020

Bibliography

Research Articles

Bournazos S, Rennie J, Hart SP, Dransfield I. (2008) Choice of anticoagulant critically affects measurement of circulating platelet-leukocyte complexes. *Arterioscler Thromb Vasc Biol.* 28(1):e2-3.

Bournazos S, Rennie J, Hart SP, Fox KA, Dransfield I. (2008) Monocyte functional responsiveness after PSGL-1-mediated platelet adhesion is dependent on platelet activation status. *Arterioscler Thromb Vasc Biol.* 28(8):1491-1498.

Bournazou I, Pound JD, Duffin R, Bournazos S, Melville LA, Brown SB, Rossi AG, Gregory CD. (2009) Apoptotic human cells inhibit migration of granulocytes via release of lactoferrin. *J Clin Invest.* 119(1):20-32.

Bournazos S, Hart SP, Chamberlain LH, Glennie MJ, Dransfield I. (2009) Association of Fcγ receptor IIa (CD32a) with lipid rafts regulates ligand binding activity. *J Immunol.* 182(12):8026-8036.

McColl A, Bournazos S, Franz S, Perretti M, Morgan BP, Haslett C, Dransfield I. (2009) Glucocorticoids induce protein S-dependent phagocytosis of apoptotic neutrophils by human macrophages. *J Immunol.* 183(3):2167-2175.

Bournazos S, Fahim A, Hart SP. (2009) Identification of fibrocytes in peripheral blood. *Am J Respir Crit Care Med.* 180(12):1279.

Bournazos S, Bournazou I, Murchison JT, Wallace WA, McFarlane P, Hirani N, Simpson AJ, Dransfield I, Hart SP. (2010) Fcγ receptor IIIb (CD16b) polymorphisms are associated with susceptibility to idiopathic pulmonary fibrosis. *Lung.* 188(6):475-481.

Bournazos S, Grinfeld J, Alexander KM, Murchison JT, Wallace WA, McFarlane P, Hirani N, Simpson AJ, Dransfield I, Hart SP. (2010) Association of FcγRIIIa R131H polymorphism with idiopathic pulmonary fibrosis severity and progression. *BMC Pulm Med.* 10:51

Bournazos S, Bournazou I, Murchison JT, Wallace WA, McFarlane P, Hirani N, Simpson AJ, Dransfield I, Hart SP. (2011) Copy number variation of *FCGR3B* is associated with susceptibility to idiopathic pulmonary fibrosis. *Respiration.* 88(2):142-149.

Smith P, DiLillo DJ, Bournazos S, Li F, Ravetch JV. (2012) Mouse model recapitulating human Fcγ receptor structural and functional diversity. *Proc Natl Acad Sci USA.* 109(16):6181-6186.

Pietzsch J, Gruell H, Bournazos S, Donovan BM, Klein F, Diskin R, Seaman MS, Bjorkman PJ, Ravetch JV, Ploss A, Nussenzweig MC. (2012) A mouse model for HIV-1 entry. *Proc Natl Acad Sci U S A.* 109(39):15859-15864.

Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, Mouquet H, Spatz LA, Diskin R, Abadir A, Zang T, Dorner M, Billerbeck E, Labitt RN, Gaebler C, Marcovecchio P, Incesu RB, Eisenreich TR, Bieniasz PD, Seaman MS, Bjorkman PJ, Ravetch JV, Ploss A, Nussenzweig MC. (2012) HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. *Nature* 492(7427):118-122.

Gruell H, Bournazos S, Ravetch JV, Ploss A, Nussenzweig MC, Pietzsch J. (2013) Antibody and antiretroviral pre-exposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model. *J Virol.* 87(15):8535-8544.

- Bournazos S, Chow SK, Abboud N, Casadevall A, Ravetch JV. (2014) Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity. *J Clin Invest*. 124(2):725-729.
- Halper-Stromberg A, Lu CL, Klein F, Horwitz JA, Bournazos S, Nogueira L, Eisenreich TR, Liu C, Gazumyan A, Schaefer U, Furze RC, Seaman MS, Prinjha R, Tarakhovsky A, Ravetch JV, Nussenzweig MC. (2014) Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. *Cell* 158(5):989-999.
- Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV. (2014) Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. *Cell* 158(6):1243-1253.
- Wang TT, Maamary J, Tan GS, Bournazos S, Davis CW, Krammer F, Schlesinger SJ, Palese P, Ahmed R, Ravetch JV. (2015) Anti-HA glycoforms drive B cell affinity selection and determine influenza vaccine efficacy. *Cell* 162(1):160-169.
- Lu CL, Murakowski DK, Bournazos S, Schoofs T, Sarkar D, Halper-Stromberg A, Horwitz JA, Nogueira L, Golijanin J, Gazumyan A, Ravetch JV, Caskey M, Arup K, Chakraborty AK, Nussenzweig MC. (2016) Enhanced clearance of HIV-1-infected cells by anti-HIV-1 broadly neutralizing antibodies *in vivo*. *Science* 352(6288):1001-4.
- Bournazos S, Gazumyan A, Seaman MS, Nussenzweig MC, Ravetch JV. (2016) Bispecific anti-HIV-1 antibodies with enhanced breadth and potency. *Cell* 165(7):1609-1620.
- Thorek DL, Watson PA, Lee SG, Ku AT, Bournazos S, Braun K, Kim K, Sjöström K, Doran MG, Lamminmäki U, Santos E, Veach D, Turkekul M, Casey E, Lewis JS, Abou DS, van Voss MR, Scardino PT, Strand SE, Alpaugh ML, Scher HI, Lilja H, Larson SM, Ulmert D. (2016) Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis. *Sci Transl Med*. 8(367):367ra167.
- Wang TT, Sewatanon J, Memoli MJ, Wrammert J, Bournazos S, Bhaumik SK, Pinsky BA, Chokephaibulkit K, Onlamoon N, Pattanapanyasat K, Taubenberger JK, Ahmed R, Ravetch JV. (2017) IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity. *Science* 355(6323):395-398.
- Li T, DiLillo DJ, Bournazos S, Giddens JP, Ravetch JV, Wang LX. (2017) Modulating IgG effector function by Fc glycan engineering. *Proc Natl Acad Sci U S A* 114(13):3485-3490.
- Raz A, Serrano A, Lawson C, Thaker M, Alston T, Bournazos S, Ravetch JV, Fischetti VA. (2017) Lysibodies are IgG Fc fusions with lysin binding domains targeting Staphylococcus aureus wall carbohydrates for effective phagocytosis. *Proc Natl Acad Sci U S A* 114(18):4781-4786.
- Casey E, Bournazos S, Mo G, Mondello P, Tan KS, Ravetch JV, Scheinberg DA. (2018) A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies. *Leukemia* 32(2):547-549.
- Keeffe JR, Van Rompay KKA, Olsen PC, Wang Q, Gazumyan A, Azzopardi SA, Schaefer-Babajew D, Lee YE, Stuart JB, Singapuri A, Watanabe J, Usachenko J, Ardeshir A, Saeed M, Agudelo M, Eisenreich T, Bournazos S, Oliveira TY, Rice CM, Coffey LL, MacDonald MR, Bjorkman PJ, Nussenzweig MC, Robbiani DF. (2018) A combination of two human monoclonal antibodies prevents Zika virus escape mutations in non-human primates. *Cell Rep*. 25(6):1385-1394.
- Weitzenfeld P, Bournazos S, Ravetch JV. (2019) Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways. *J Clin Invest*. 129(9):3952-3962.
- Bournazos S, DiLillo DJ, Goff AJ, Glass PJ, Ravetch JV. (2019) Differential requirements for FcγR engagement by protective antibodies against Ebola virus. *Proc Natl Acad Sci U S A*. 116(40):20054-20062.
- Van Rompay KKA, Coffey LL, Kapoor T, Gazumyan A, Keesler RI, Jurado A, Peace A, Agudelo M, Watanabe J, Usachenko J, Singapuri A, Immareddy R, Ardeshir A, Stuart JB, Bournazos S, Ravetch JV, Balderes PJ,

- Lorenz IC, Esswein SR, Keeffe JR, Bjorkman PJ, Wang Q, Rice CM, MacDonald MR, Nussenzweig MC, Robbiani DF. (2020) A combination of two human monoclonal antibodies limits fetal damage by Zika virus in macaques. *Proc Natl Acad Sci U S A*. 117(14):7981-7989.
- Thulin NK, Brewer RC, Sherwood R, Bournazos S, Edwards KG, Ramadoss NS, Taubenberger JK, Memoli M, Gentles AJ, Jagannathan P, Zhang S, Libraty DH, Wang TT. (2020) Maternal anti-dengue IgG fucosylation predicts susceptibility to dengue disease in infants. *Cell Rep*. 31(6):107642.
- Borghi S, Bournazos S, Thulin NK, Li C, Gajewski A, Sherwood RW, Zhang S, Harris E, Jagannathan P, Wang LX, Ravetch JV, Wang TT. (2020) FcRn, but not FcγRs, drives maternal-fetal transplacental transport of human IgG antibodies. *Proc Natl Acad Sci U S A*. 117(23):12943-12951.
- Bournazos S, Corti D, Virgin HW, Ravetch JV. (2020) Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection. *Nature*. 588(7838):485-490.
- Schäfer A, Muecksch F, Lorenzi JCC, Leist SR, Cipolla M, Bournazos S, Schmidt F, Maison RM, Gazumyan A, Martinez DR, Baric RS, Robbiani DF, Hatzioannou T, Ravetch JV, Bieniasz PD, Bowen RA, Nussenzweig MC, Sheahan TP. (2021) Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection *in vivo*. *J Exp Med*. 218(3):e20201993.
- Li C, Chong G, Zong G, Knorr DA, Bournazos S, Aytenfisu AH, Henry GK, Ravetch JV, MacKerell AD Jr, Wang LX. (2021) Site-selective chemoenzymatic modification on the core fucose of an antibody enhances its Fcγ receptor affinity and ADCC activity. *J Am Chem Soc*. 143(20):7828-7838.
- Bournazos S, My Vo HT, Duong V, Auerswald H, Ly S, Sakuntabhai A, Dussart P, Cantaert T, Ravetch JV. (2021) Antibody fucosylation predicts disease severity in secondary dengue infection. *Science*. 372(6546):1102-1105.
- Ou C, Li C, Zhang R, Yang Q, Zong G, Dai Y, Francis RL, Bournazos S, Ravetch JV, Wang LX. (2021) One-pot conversion of free sialoglycans to functionalized glycan oxazolines and efficient synthesis of homogeneous antibody-drug conjugates through site-specific chemoenzymatic glycan remodeling. *Bioconjug Chem*. 32(8):1888-1897.
- Yamin R, Jones AT, Hoffmann HH, Schäfer A, Kao KS, Francis RL, Sheahan TP, Baric RS, Rice CM, Ravetch JV, Bournazos S. (2021) Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. *Nature*. 599(7885):465-470.
- Gupta A, Smith P, Bournazos S, Ravetch JV. (2022) A novel mouse strain optimized for chronic human antibody administration. *Proc Natl Acad Sci U S A*. 119(10):e2123002119.
- Herati RS, Knorr DA, Vella LA, Silva LV, Chilukuri L, Apostolidis SA, Huang AC, Muselman A, Manne S, Kuthuru O, Staupe RP, Adamski SA, Kannan S, Kurupati RK, Ertl HCJ, Wong JL, Bournazos S, McGettigan S, Schuchter LM, Kotecha RR, Funt SA, Voss MH, Motzer RJ, Lee CH, Bajorin DF, Mitchell TC, Ravetch JV, Wherry EJ. (2022) PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine. *Nat Immunol*. 23(8):1183-1192.
- Kao KS, Gupta A, Zong G, Li C, Kerschbaumer I, Borghi S, Achkar JM, Bournazos S, Wang LX, Ravetch JV. (2022) Synthetic nanobodies as tools to distinguish IgG Fc glycoforms. *Proc Natl Acad Sci* 119(48):e2212658119.

Review Articles

- Bournazos S, Woof JM, Hart SP, Dransfield I. (2009) Functional and clinical consequences of Fc receptor polymorphic and copy number variants. *Clin Exp Immunol*. 157(2):244-254.
- Pincetic A, Bournazos S, DiLillo DJ, Maamary J, Wang TT, Dahan R, Fiebiger BM, Ravetch JV. (2014) Type I and type II Fc receptors regulate innate and adaptive immunity. *Nat Immunol*. 15(8):707-716.

- Bournazos S, DiLillo DJ, Ravetch JV. (2015) The role of Fc-FcγR interactions in IgG-mediated microbial neutralization. *J Exp Med*. 212(9):1361-1369.
- Bournazos S, Ravetch JV. (2015) Fcγ receptor pathways during active and passive immunization. *Immunol Rev*. 268(1):88-103.
- Lewis GK, Pazgier M, Evans DT, Ferrari G, Bournazos S, Parsons MS, Bernard NF, Finzi A. (2017) Beyond viral neutralization. *AIDS Res Hum Retroviruses* 33(8):760-764.
- Bournazos S, Ravetch JV. (2017) Anti-retroviral antibody FcγR-mediated effector functions. *Immunol Rev*. 275(1):285-295.
- Bournazos S, Ravetch JV. (2017) Attenuated vaccines for augmented immunity. *Cell Host Microbe* 21(3):314-315.
- Bournazos S, Wang TT, Dahan R, Maamary J, Ravetch JV. (2017) Signaling by antibodies: recent progress. *Annu Rev Immunol*. 35:285-311.
- Bournazos S, Ravetch JV. (2017) Diversification of IgG effector functions. *Int Immunol*. 29(7):303-310.
- Bournazos S, Ravetch JV. (2017) Fcγ receptor function and the design of vaccination strategies. *Immunity* 47(2):224-233.
- Wang TT, Bournazos S, Ravetch JV. (2018) Immunological responses to influenza vaccination: lessons for improving vaccine efficacy. *Curr Opin Immunol*. 53:124-129.
- Bournazos S, Gupta A, Ravetch JV. (2020) The role of IgG Fc receptors in antibody-dependent enhancement. *Nat Rev Immunol*. 20(10):633-643.
- Pihlstrom N, Bournazos S. (2023) Engineering strategies of Anti-HIV antibody therapeutics in clinical development. *Curr Opin HIV AIDS*. doi: 10.1097/COH.0000000000000796.

Book Chapters

- Bournazos S, DiLillo DJ, Ravetch JV. (2014) Humanized mice to study FcγR function. *Curr Top Microbiol Immunol*. 382:237-248.
- Bournazos S, Wang TT, Ravetch JV. (2016) The role and function of Fcγ Receptors on myeloid cells. *Microbiol Spectr*. 4(6).
- Bournazos S. (2019) IgG Fc Receptors: Evolutionary Considerations. *Curr Top Microbiol Immunol*. 423:1-11.

Research Funding

Current Support

- | | |
|---|---------------------|
| R01-AI137276 (Bournazos, PI) | 09/01/18 – 08/31/23 |
| National Institute of Allergy and Infectious Diseases (NIAID) | |
| Mechanisms of antibody-dependent enhancement during dengue infection. | |
| Role: Principal Investigator | |
| R01-CA244327 (Bournazos, PI) | 07/01/20 – 06/30/25 |
| National Cancer Institute (NCI) | |
| Novel transgenic mouse models addressing outstanding translational barriers in antibody-based therapeutics. | |
| Role: Principal Investigator | |
| U19-AI111825 (Ravetch, PI) | 04/01/14 – 03/31/24 |
| National Institute of Allergy and Infectious Diseases (NIAID) | |

Integrating innate and adaptive pathways in vaccine responses.

Role: Principal Investigator (Animal Core), Co-Investigator (Project 1)

INV-035597 (Ravetch, PI)

07/19/21 – 07/19/24

Bill and Melinda Gates Foundation

Early events and role of FcR pathways in immunity to mRNA vaccines.

Role: Co-Investigator

R01-AI145870 (Ravetch/Palese, PI)

07/01/19 – 06/30/24

National Institute of Allergy and Infectious Diseases (NIAID)

Development of vaccination strategies to elicit broadly protective immunity against influenza.

Role: Co-Investigator

Collaborative Influenza Vaccine Innovation Centers (Ahmed/Krammer, PI) 08/01/19 – 07/31/26

National Institute of Allergy and Infectious Diseases (NIAID)

CRUIVV: Center for Research, Universal Influenza Virus Vaccines.

Role: Co-Investigator

R01-AI153441 (Ravetch/Anthony, PI)

07/01/20 – 06/30/24

National Institute of Allergy and Infectious Diseases (NIAID)

Examining IgG4 sialylation as a gain of function post-translation modification in IgG4-related disease.

Role: Co-Investigator

Previous Support

3R01AI145870-02S1 (Ravetch, PI)

07/01/20 – 06/30/22

National Institute of Allergy and Infectious Diseases (NIAID)

Evaluation of the FcγR mechanisms in the antibody-dependent enhancement of SARS-CoV-2 infection

Role: Co-Investigator

R01-AI129795 (Ravetch/Nussenzweig, PI)

07/01/17 – 06/30/22

National Institute of Allergy and Infectious Diseases (NIAID)

Optimization of Fc effector activity of anti-HIV antibodies to target HIV reservoir.

Role: Co-Investigator

3U19AI111825-07S1 (Ravetch, PI)

04/01/20 – 03/31/22

National Institute of Allergy and Infectious Diseases (NIAID)

Characterization of the antibody responses elicited upon SARS-CoV-2 infection.

Role: Co-Investigator

Thwarting Influenza with RNA-powered Modulators (ThIRM) (Santagelo, PI)

04/01/19 – 08/31/21

Defense Advanced Research Projects Agency (DARPA)

Thwarting Influenza with RNA-powered Modulators.

Role: Co-Investigator

R01-AI137276-02S1 (Bournazos, PI)

05/18/20 – 08/31/21

National Institute of Allergy and Infectious Diseases (NIAID)

Mechanisms of antibody-dependent enhancement of SARS-CoV-2 infection.

Role: Principal Investigator

SP008-SC007 A01 (Bournazos, PI)

04/01/19 – 03/31/21

University of Alabama at Birmingham via NIAID

Modulating the antibody response to vaccination through targeting the CD40 axis.

Role: Principal Investigator

FastGrants	05/01/20 – 10/31/20
Development of novel mouse strains for the study of COVID-19	
Role: Co-Principal Investigator	
OPP1188461 (Ravetch, PI)	11/27/17 – 05/31/20
Bill and Melinda Gates Foundation	
Enhancing IgG transfer to prevent perinatal infections.	
Role: Co-Investigator	
U19-AI109946 (Palese, PI)	04/01/14 – 03/31/19
National Institute of Allergy and Infectious Diseases (NIAID)	
Mechanisms of Fc-dependent, broad-spectrum, humoral immunity against influenza.	
Role: Co-Investigator	
Gilead (Bournazos, PI)	06/01/17 – 05/31/19
Development and evaluation of anti-HIV-1 antibodies with potent cytotoxic activity against HIV-1 infected cells.	
Role: Principal Investigator	
U01-AI115651 (Ravetch, PI)	02/01/15 – 01/31/20
National Institute of Allergy and Infectious Diseases (NIAID)	
Dengue virus infection in India.	
Role: Co-Investigator	
Robertson Therapeutic Fund (Ravetch, PI)	11/01/18 – 10/31/20
Pre-clinical development of immune complex-based immunogens to increase the breadth of the seasonal influenza vaccination.	
Role: Co-Investigator	
W31P4Q-14-1-0010 (Ahmed, PI)	09/22/14 – 12/31/17
Defense Advanced Research Projects Agency (DARPA)	
Development of antibody therapeutics against Ebola; Project 3: Mechanisms of IgG-Mediated Protection Against Ebola Virus.	
Role: Co-Investigator	
Investment ID INV-023152	04/12/20 – 03/15/21
Bill and Melinda Gates Foundation	
COVID-19: Hamster FcγR evaluation	
Role: Co-Investigator	
amfAR Mathilde Krim Fellowship (Bournazos, PI)	07/01/16 – 06/30/17
American Foundation for AIDS research (amfAR)	
Optimization of anti-HIV-1 antibodies for prevention and therapy.	
Role: Principal Investigator	
CCHI Pilot Project U19-AI11825-03 (Bournazos, PI)	04/01/16 – 03/31/17
National Institute of Allergy and Infectious Diseases (NIAID)	
The role of IgG3 in immunity.	
Role: Principal Investigator	
amfAR Mathilde Krim Fellowship (Bournazos, PI)	10/01/14 – 09/30/16
American Foundation for AIDS research (amfAR)	
Fc effector activity of anti-HIV-1 broadly neutralizing antibodies.	
Role: Principal Investigator	

Postdoctoral Fellowship 13POST14100003 (Bournazos, PI) 01/01/13 – 09/30/14
American Heart Association (Founders Affiliate)
The immunomodulatory role of Fc effector pathways in the protection against atherosclerosis.
Role: Principal Investigator

Career Development Award (Bournazos, PI) 03/01/11 – 01/01/13
Northeast Biodefense Center/National Institute of Allergy and Infectious Diseases (NIAID)
Role of Fcγ receptors in antibody-mediated protection against microbial infection.
Role: Principal Investigator

PhD Fellowship FS/05/119/19568 (Bournazos, PI) 10/01/05 – 08/30/09
British Heart Foundation, UK.
Molecular mechanisms of the regulation of immune complex binding to neutrophil CD32.
Role: Principal Investigator